ARCHIVES

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

The President’s Cancer Panel publishes its annual report

May 6, 2011

Edelson To Step Down As Yale Center Director.

January 11, 2008

Clinical Research; Duke Received Several Warnings from OPRR, Letters Indicate

May 14, 1999

Research Opportunities In Pancreas Cancer Described; Top Priority Set

December 21, 1973

‘Dear Dr. Bick’: Letters Reflect Turmoil Over Conflict Of Interest

January 26, 1990

Presidents’ FY93 Budget Holds NCI To $2 Billion, Gives NIH 5% Increase; Coalition ‘Disapionted’

February 7, 1992